[Does adenosine administration during the early reperfusion period affect ischemic preconditioning?].
We hypothesized that the adenosine administration during the early reperfusion period might affect ischemic preconditioning (IPC) and might reduce infarct size and enhance post-ischemic functional recovery. Twenty-four anesthetized rabbits underwent 30 min. normothermic global ischemia with 120 min. reperfusion in a buffer-perfused isolated, paced heart model and divided into four groups. Global ischemic hearts (GI, n = 6) were subjected to 30 min. global ischemia without intervention. Control hearts (n = 6) were subjected to perfusion without ischemia. Ischemic preconditioned hearts (IPC, n = 6) were subjected to one cycle of 5 min. global ischemia and 5 min. reperfusion prior to global ischemia. IPC + Ado hearts (n = 6) received IPC and adenosine administration (100 m mol/L) during 3 min. early reperfusion period. Post-ischemic functional recovery was better in IPC + Ado hearts as compared to GI and IPC hearts, but the effect of post-ischemic functional recovery in IPC + Ado hearts became weaker during 120 min. reperfusion after prolong ischemic insult. Infarct size were 1.0 +/- 0.3% in Control hearts, 32.9 +/- 5.1% in GI hearts, 13.8 +/- 1.3% in IPC hearts and 8.1 +/- 0.9% in IPC + Ado hearts Infarct size in IPC hearts was significantly decreased (p < 0.01) as compared to GI hearts. The reduction rate against myocardial necrosis in IPC + Ado hearts versus GI hearts was higher as compared to IPC hearts versus GI hearts (p < 0.001, IPC + Ado hearts vs GI hearts; p < 0.01, IPC hearts vs GI hearts; p = ns, IPC + Ado hearts vs Control hearts). These data suggest that adenosine administration during the early reperfusion period reinforce IPC effect and reduce myocardial reperfusion injury. Cardiomyoprotective effects of IPC and exogenous adenosine are exerted during early reperfusion after coronary occlusion in the isolated perfused rabbit hearts.
Uematsu
M
M
Division of Cardiothoracic Surgery, Beth Israel Deaconess Medical Center, Boston, Massaachusetts, USA.
Okada
M
M
D000241:Adenosine / Q000494:pharmacology*; D000818:Animals; D002317:Cardiovascular Agents / Q000494:pharmacology*; D019157:Ischemic Preconditioning, Myocardial; D015425:Myocardial Reperfusion; D015428:Myocardial Reperfusion Injury / Q000517:prevention & control; D011817:Rabbits
D002317:Cardiovascular Agents; D000241:Adenosine